CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

A new study has revealed that the gene HMGN1 is a key driver of congenital heart defects (CHDs) in Down syndrome. Using ...

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...

"The CRISPR technology was introduced as an mRNA," Coller said. "That is the critical feature that was necessary to get this ...

Martin Kampmann’s work, supported by the National Institutes of Science (NIH), maps cellular “decision points” that determine ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $62.56, moving -2.51% from the previous trading session. Elsewhere, the Dow saw a downswing of 0.16%, while the tech-heavy Nasdaq ...

Explore how oligonucleotides are reshaping therapeutics, diagnostics and CRISPR with rapid, scalable and personalized ...

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are underway, and life-saving treatments have been developed.

VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a non-exclusive license agreement with Mammoth Biosciences, Inc. for the use of select CRISPR-based ...

A lthough still in its early days, CRISPR has already been called the most powerful scientific tool of the century. Using ...

Chocolate prices have been rising due to complications in the supply chain, but Penn State researchers have made a ...